Download Avant Diagnostics Presents at 2016 ASCO Annual Meeting

Avant Diagnostics Announces Data Presentations at 2016 ASCO Annual Meeting
SCOTTSDALE, AZ and GAITHERSBERG, MD – May 19, 2016 - Avant Diagnostics, Inc.
(“Avant”) (OTCQB: AVDX), an innovative molecular diagnostics company, today announced the
acceptance of two posters for presentation at the upcoming American Society of Clinical
Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.
“We look forward to presenting this important work that was completed with leading clinical
collaborators, demonstrating the power of our reverse phase protein array (RPPA) pathway
analysis technology,” said Glenn D. Hoke, PhD, incoming Chief Scientific Officer at Avant. “As
we move forward, we will be looking to build upon this work by expanding our clinical and
collaboration network in order to provide drug development companies and clinicians with the
necessary information to better inform treatment and trial recruitment decisions to the ultimate
benefit of patients.”
POSTER PRESENTATION #1
Sunday June 5, 8:00 AM – 11:30 AM CT
Abstract #558: Reverse-phase protein microarray (RPPA) analysis of PD-L1 and growth factor
receptor signal transduction pathways in hormone receptor (HR)-positive primary breast cancer
tissue and correlation with relapse.
Principle Investigator: Alan Lipton, MD, Penn State Hershey Medical Center
Presenter: Suhail M. Ali, MD, MBBS, Penn State Hershey Medical Center, VA Medical Center
Session: Breast Cancer-HER2/ER
Poster Display: Hall A; Poster Board 46; 8:00 AM – 11:30 AM CT
POSTER PRESENTATION #2
Monday June 6, 1:00 PM – 4:30 PM CT
Abstract # 11527: Androgen receptor activation in HER2-negative breast cancer liver
metastases.
Principle Investigator: Joyce O’Shaughnessy, MD, Baylor University Center, Texas Oncology
Presenter: Corinne Ramos, Ph.D., Theranostics Health, Gaithersburg, MD
Session: Tumor Biology
Poster Display: Hall A; Poster Board 224; 1:00 PM – 4:30 PM CT
ASCO 2015 Annual Meeting Posters on RPPA Assay
HER3 and paxillin signaling in ER+ HER2- metastatic breast cancer patients receiving letrozole
vs. letrozole plus dasatinib in a randomized phase II trial.
HER2-amplified residual disease refractory to preoperative chemotherapy plus Trastuzumab,
Lapatinib, or both shows HER3, PI3K, and JAK2 pathway activation on reverse-phase protein
microarray.
Identifying molecular targets and mechanisms of treatment resistance in Inflammatory Breast
Cancer using next-generation sequencing and reverse-phase protein microarrays.
About Avant Diagnostics, Inc.
Avant is a medical diagnostic technology company that specializes in biomarker tests that are
being developed in the areas of oncology and neurology. Avant provides personalized medicine
diagnostic testing capabilities through its TheraLink® Diagnostic Assays, primarily for breast
cancer, to assist clinical oncologists in identify likely responders for roughly 30 FDA-approved
drug treatment regimens through its CLIA/CAP. Avant is the leading developer of proteomic
technologies for measuring the activation status of key signaling pathways across several
different cancer types, including breast, ovarian and pancreatic that are instrumental in the
development of companion diagnostics for molecular-targeted therapies. Avant has used these
proteomic technologies to support the drug development programs of many of the top
biopharmaceutical companies in the world. For more information please visit
www.theranosticshealth.com.
Avant is also developing OvaDx® for use in monitoring women diagnosed previously with
ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation
of the immune system in blood samples in response to ovarian tumor cell development. Preclinical research studies with OvaDx® indicate high sensitivity and specificity for all types and
stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed
epithelial, mucinous, serous, and ovarian adenocarcinoma.
Avant’s neurology division owns the rights to MSPrecise™, a proprietary next-generation DNA
sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple
sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the
Lymphocyte Proliferation test (LymPro Test™for Alzheimer's disease, which was developed by
Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for
the diagnosis of Parkinson's disease (NuroPro).
For further information please visit www.Amarantus.com, or connect with the Company on
Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend,"
among others. These forward-looking statements are based on Avant's current expectations
and actual results could differ materially. There are a number of factors that could cause actual
events to differ materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, substantial competition; our ability to continue as a going
concern; our need for additional financing; uncertainties with respect to lengthy and expensive
clinical trials, that results of earlier studies and trials may not be predictive of future trial results;
and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. There are no guarantees that future clinical trials discussed in this press release will
be completed or successful, or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Avant does not undertake an obligation to
update or revise any forward-looking statement except as required by law. Investors should
read the risk factors set forth in Avant's Form 10-K filed with the Securities and Exchange
Commission on January 13, 2016, and other periodic reports filed with the Securities and
Exchange Commission.
Investor and Media Contact:
Ascendant Partners, LLC
Fred Sommer
732-410-9810
[email protected]
###